Crossmark

Is Laryngeal Hypersensitivity Phenotype the Commonest Presentation Amongst Patients with Refractory Chronic Cough?

Published Online: 2024-12-02

Published Print: 2025-12

Authors

Taylor, Analisa

Stark, Amanda

Sundar, Krishna M.
License Information

Text and Data Mining valid from 2024-12-02

Version of Record valid from 2024-12-02
More Information

Article History

Received: 18 July 2024

Accepted: 5 October 2024

First Online: 2 December 2024

Declarations

:

: KMS has served on advisory board for GlaxoSmithKline Pharma on cough therapeutics (Camlipixant). AT and AS have no conflicts of interest to disclose.

Document is current